Physician profile
Jonathan D Leffert
NPI 1891720785
$4,316.62
in general payments reported to CMS, 2019-2025
40 companies · $1,159 in 2025
The $1,159 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $719 · 2020: $159 · 2021: $128 · 2022: $563 · 2023: $741 · 2024: $847 · 2025: $1,159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,408 · Honoraria: $300 · Education: $39.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,407.56 |
| Honoraria | $300.00 |
| Education | $39.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $341.34 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Tandem Diabetes Care, INC. | $339.50 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amgen INC. | $326.82 | 2019-2025 | Evenity, Prolia, Tepezza |
| Lilly USA, LLC | $303.53 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Chiesi USA, INC. | $300.00 | 2025 | Mycapssa |
| Sanofi-Aventis U.S. LLC | $262.51 | 2019-2025 | |
| Mannkind Corporation | $219.39 | 2021-2025 | Afrezza |
| Abbott Laboratories | $216.10 | 2019-2025 | Freestyle Libre 3 |
| Cequr Corporation | $174.29 | 2022-2025 | Cequr Simplicity |
| Medtronic, INC. | $165.21 | 2021-2025 | Inpen Smart Insulin Delivery System, Minimed 780g |
| Dexcom, INC. | $160.45 | 2019-2025 | Dexcom G6 Transmitter |
| Insulet Corporation | $153.57 | 2019-2025 | Omnipod |
| Radius Health, INC. | $136.68 | 2023-2025 | Tymlos |
| Xeris Pharmaceuticals, INC. | $133.74 | 2022-2024 | Recorlev, Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.96 | 2019-2024 | Jardiance |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Leffert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.